AstraZeneca in new vaccine turbulence as Fauci-led US institute seeks timely data

Shares in AstraZeneca fell by about 1.5% after the US National Institute for Allergy and Infectious Diseases indicated that promising US trial results may give an 'incomplete' view of the vaccine's efficacy

Anthony Fauci, director of the US National Institute for Allergy and Infectious Diseases.

Shares in AstraZeneca fell by about 1.5% after a US institute headed by leading immunologist Anthony Fauci indicated that promising US trial results may give an “incomplete” view of the vaccine's efficacy.

The US National Institute for Allergy and Infectious Diseases said the independent panel charged with ensuring the safety and accuracy of the vaccine trial had expressed concern that results included outdated information.